Skip to main content

Table 4 Fast and slow progressors in the SCarlet RoAD population

From: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

Variable, median score (Q1; Q3) Change from baseline at week 104 (n = 310a)
Slow progressors (n = 202) Fast progressors (n = 108)
  Placebo (n = 70) Gantenerumab
105 mg
(n = 57)
Gantenerumab
225 mg
(n = 75)
Placebo (n = 35) Gantenerumab
105 mg
(n = 47)
Gantenerumab
225 mg
(n = 26)
Primary endpoint
 CDR-SB 0.5 (0, 1.5) 0.5 (0, 2) 1.0 (0, 1.5) 1.5 (0.5, 3) 1.0 (0, 2.75) 2.0 (1, 2.88)
Secondary endpoints
 ADAS-Cog 13 3.34 (−1.41, 8.41) 3.5 (−2.5, 6.25) 3.33 (−0.34, 8.67) 6.0 (2.34, 12.17) 4.84 (1.5, 7.92) 2.66 (0.67, 7.5)
 CANTAB −1.43 (−2.52, −0.31) −1.14 (−3, 0.97) −0.99 (−3.22, 0.56) −2.42 (−4.09, 0.07) −1.31 (−3.27, 0.25) −0.81 (−1.98, 0.69)
 FAQ 1 (0, 5) 1 (0, 7) 2 (0, 6) 5 (2.5, 8) 6 (2, 8.5) 4 (1, 9)
 MMSE −1 (−4, 0) −1 (−4, 0.25) −2 (−3, 0) −3.5 (−4.75, −2) −3 (−4.5, 0) −2 (−4, 0)
  1. Abbreviations: ADAS-Cog 13 Alzheimer’s Disease Assessment Scale–Cognitive subscale, CANTAB Cambridge Neuropsychological Test Automated Battery, CDR-SB Clinical Dementia Rating Sum of Boxes, FAQ Functional Activities Questionnaire, MMSE Mini Mental State Examination
  2. aSix patients completing study drug treatment had missing efficacy assessment at the week 104 visit time window